6. A history of previously treated brain metastases is allowed, provided that at least 14 days have lapsed between radiation and initiation of pembrolizumab. Any lesion present at the time of WBRT or included in the stereotactic radiotherapy field (or within 2mm of the treated lesion) will NOT be considered evaluable unless it is new or documented to have progressed since treatment.